CA3028160C - Formulation administrable oralement - Google Patents

Formulation administrable oralement Download PDF

Info

Publication number
CA3028160C
CA3028160C CA3028160A CA3028160A CA3028160C CA 3028160 C CA3028160 C CA 3028160C CA 3028160 A CA3028160 A CA 3028160A CA 3028160 A CA3028160 A CA 3028160A CA 3028160 C CA3028160 C CA 3028160C
Authority
CA
Canada
Prior art keywords
formulation
pharmaceutical agent
acid
gum
gum base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3028160A
Other languages
English (en)
Other versions
CA3028160A1 (fr
Inventor
Allen Greenspoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA3028160A priority Critical patent/CA3028160C/fr
Publication of CA3028160A1 publication Critical patent/CA3028160A1/fr
Application granted granted Critical
Publication of CA3028160C publication Critical patent/CA3028160C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)

Abstract

Une formule de gomme à mâcher comprenant une base de gomme, et des particules dun agent pharmaceutique de taille comprise entre 50 et 2 000 µm est décrite. La formulation comprend 0,5 à 30 % de particules dagent pharmaceutiques. Une formulation liquide comprenant les particules dun agent pharmaceutique est également décrite.
CA3028160A 2016-07-28 2016-07-28 Formulation administrable oralement Active CA3028160C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3028160A CA3028160C (fr) 2016-07-28 2016-07-28 Formulation administrable oralement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA3028160A CA3028160C (fr) 2016-07-28 2016-07-28 Formulation administrable oralement
CA2937471A CA2937471C (fr) 2016-07-28 2016-07-28 Formulation administrable oralement

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2937471A Division CA2937471C (fr) 2016-07-28 2016-07-28 Formulation administrable oralement

Publications (2)

Publication Number Publication Date
CA3028160A1 CA3028160A1 (fr) 2016-09-29
CA3028160C true CA3028160C (fr) 2021-03-30

Family

ID=56998774

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2937471A Active CA2937471C (fr) 2016-07-28 2016-07-28 Formulation administrable oralement
CA3028160A Active CA3028160C (fr) 2016-07-28 2016-07-28 Formulation administrable oralement

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2937471A Active CA2937471C (fr) 2016-07-28 2016-07-28 Formulation administrable oralement

Country Status (1)

Country Link
CA (2) CA2937471C (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
WO2018075665A1 (fr) * 2016-10-20 2018-04-26 Axim Biotechnologies, Inc. Composition de gomme à mâcher comprenant des cannabinoïdes et des agonistes et/ou des antagonistes opioïdes
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3089994A1 (fr) 2018-01-31 2019-08-08 Canopy Holdings, LLC Poudre de chanvre
CA3050473C (fr) 2018-08-28 2021-05-18 Chirosyn Discovery Technologies Inc. Composition alcaline de cannabidiol
WO2020041860A1 (fr) * 2018-08-28 2020-03-05 Chirosyn Discovery Technologies Inc. Composition alcaline de cannabidiol
US20210393572A1 (en) * 2018-09-28 2021-12-23 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
CA3119729A1 (fr) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthese du cannabigerol
CA3120213A1 (fr) * 2018-11-30 2020-06-04 Canopy Growth Corporation Formulations de cannabinoides ou de composes derives du cannabis solubles dans l'eau, methode de fabrication et utilisation
US11191720B2 (en) 2019-01-25 2021-12-07 Nordiccan A/S Chewing gum with improved delivery of cannabinoids
US11166910B2 (en) * 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
US11154496B2 (en) 2019-01-25 2021-10-26 Nordiccan A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11406593B2 (en) 2019-01-25 2022-08-09 Nordiccan A/S Cannabinoid chewing gum with high intensity sweeteners
US11013685B2 (en) 2019-01-25 2021-05-25 Nordiccan A/S Cannabinoid chewing gum with improved release of cannabinoids
US10933017B2 (en) 2019-03-01 2021-03-02 Nordiccan A/S Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11253473B2 (en) 2019-03-01 2022-02-22 Nordiccan A/S Method of producing tableted cannabinoid chewing gum
US10799450B2 (en) 2019-03-01 2020-10-13 Medcan Pharma A/S Tableted cannabinoid chewing gum with layered structure
US11471405B2 (en) 2019-03-01 2022-10-18 Nordiccan A/S Tableted chewing gum with enhanced delivery of cannabinoids

Also Published As

Publication number Publication date
CA3028160A1 (fr) 2016-09-29
CA2937471C (fr) 2019-02-05
CA2937471A1 (fr) 2016-09-29

Similar Documents

Publication Publication Date Title
AU2020257071B2 (en) Novel orally adminstrable formulation
CA3028160C (fr) Formulation administrable oralement
KR101074271B1 (ko) 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
CN104271114B (zh) 含鸦片剂肠释放小珠的口腔膜剂
EP1648421B1 (fr) Films a dissolution orale
EP2821066B1 (fr) Film à haute teneur et à dissolution rapide à goût amer masqué comprenant du sildénafil comme principe actif
CN110621307A (zh) 含有烟碱的口香糖组合物
WO2013171146A1 (fr) Film oral contenant un résinate d'opiate à libération entérique
US8968770B2 (en) Multi-part kit comprising a chewing gum and further a flavor containing formulation
US20240156844A1 (en) Orally administrable formulation
KR101440808B1 (ko) 실데나필 또는 이의 약제학적으로 허용되는 염을 고함량으로 포함하는 속용필름

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181219